Three cases of viridans group streptococcal bacteremia in children with febrile neutropenia and literature review

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 11-12, 2003, Pages 873-876

  Danilatou, Vassiliki ^a   Mantadakis, Elpis ^a   Galanakis, Emmanouil ^a   Christidou, Athanassia ^a   Stiakaki, Eftichia ^a   Kalmanti, Maria ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTACID AGENT; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; CISPLATIN; CLINDAMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DALFOPRISTIN PLUS QUINUPRISTIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPENEM; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; THIOTEPA; VANCOMYCIN; VINCRISTINE;

ADOLESCENT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATION; BRAIN TUMOR; CASE REPORT; CHILD; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; REVIEW;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTEREMIA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; MALE; NEUTROPENIA; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STREPTOCOCCAL INFECTIONS; TREATMENT OUTCOME; VIRIDANS STREPTOCOCCI;

EID: 0346338394     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540310017159     Document Type: Review

References (31)

1. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with haematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-10.
2. Karchmer AW. Nosocomial bloodstream infections: organisms, risk factors, and implications. Clin Infect Dis 2000; 31(Suppl 4): S139-43.
3. Johnson CC, Tunkel AR. Viridans streptococci. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia, Churchill-Livingston, 2000, p. 2167-83.
4. Hohwy J, Reinholdt J, Kilian M. Population dynamics of Streptococcus mitis in its natural habitat. Infect Immun 2001; 69: 6055-63.
5. Kawamura Y, Whiley RA, Shu SE, Ezaki T, Hardie JM. Genetic approaches to the identification of the mitis group within the genus Streptococcus. Microbiology 1999; 145: 2605-13.
6. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002; 34: 1524-9.
7. Marron A, Carratala J, Gonzalez-Barca E, Fernandez-Sevilla A, Alcaide F, Gudiol F. Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 2000; 31: 1126-30.
8. Tanzer JM, Livingston J, Thompson AM. The microbiology of primary dental caries in humans. J Dent Educ 2001; 65: 1028-37.
9. Galanakis E, Kritikou-Pliota E, Pappa C, Siamopoulou A, Papadopoulou ZL. Streptococcus mitis septicaemia and hepatitis. Scand J Infect Dis 2000; 32: 214-5.
10. Graber CJ, de Almeida KN, Atkinson JC, Javaheri D, Fukuda CD, Gill VJ, et al. Dental health and viridans streptococcal bacteremia in allogeneic haematopoietic stem cell transplant recipients. Bone Marrow Transplant 2001; 27: 537-42.
11. Berner R, Schumacher RF, Bartelt S, Forster J, Brandis M. Predisposing conditions and pathogens in bacteremia in hospitalized children. Eur J Clin Microbiol Infect Dis 1998; 17: 337-40.
12. Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994; 97: 256-64.
13. Levy CS, Kogulan P, Gill VJ, Croxton MB, Kane JG, Lucey DR. Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Clin Infect Dis 2001; 33: 577-9.
14. Stock JH, Sahn DJ. Endocarditis in the paediatric population. Curr Treat Options Cardiovasc Med 2000; 2: 481-8.
15. Bowden GH. Mutans streptococci caries and chlorhexidine. J Can Dent Assoc 1996; 62: 700, 703-7.
16. Elting LS, Bodey GP, Keefe BH. Septicaemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14: 1201-7.
17. Bruckner LB, Korones DN, Karnauchow T, Hardy DJ, Gigliotti F. High incidence of penicillin resistance among alpha-haemolytic streptococci isolated from the blood of children with cancer. J Pediatr 2002; 140: 20-6.
18. Martino R, Manteiga R, Sanchez I, Brunet S, Sureda A, Badell I, et al. Viridans streptococcal shock syndrome during bone marrow transplantation. Acta Haematol 1995; 94: 69-73.
19. Steiner M, Villablanca J, Kersey J, Ramsay N, Haake R, Ferrieri P, Weisdorf D. Viridans streptococcal shock in bone marrow transplantation patients. Am J Haematol 1993; 42: 354-8.
20. Barker GJ. Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Support Care Cancer 1999; 7: 17-20.
21. Frentzen M, Ploenes K, Braun A. Clinical and microbiological effects of local chlorhexidine applications. Int Dent J 2002; 52: 325-9.
22. Zanela NL, Bijella MF, Rosa OP. The influence of mouth rinses with antimicrobial solutions on the inhibition of dental plaque and on the levels of mutans streptococci in children. Pesqui Odontol Bras 2002; 16: 101-6.
23. Dodd MJ, Larson PJ, Dibble SL, Miaskowski C, Greenspan D, MacPhail L, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996; 23: 921-7.
24. Barker GJ, Call SK, Gamis AS. Oral care with vancomycin paste for reduction in incidence of alpha-haemolytic streptococcal sepsis. J Pediatr Hematol Oncol 1995; 17: 151-5.
25. Pizzo PA, Ladisch S, Witebsky FG. Alpha-haemolytic streptococci: clinical significance in the cancer patient. Med Pediatr Oncol 1978; 4: 367-70.
26. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996; 40: 891-4.
27. Wisplinghoff H, Reinert RR, Cornely O, Seifert H. Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. J Clin Microbiol 1999; 37: 1876-80.
28. Poutanen SM, de Azavedo J, Willey BM, Low DE, MacDonald KS. Molecular characterization of multidrug resistance in Streptococcus mitis. Antimicrob Agents Chemother 1999; 43: 1505-7.
29. Balkundi DR, Murray DL, Patterson MJ, Gera R, Scott-Emuakpor A, Kulkarni R. Penicillin-resistant Streptococcus mitis as a cause of septicaemia with meningitis in febrile neutropenic children. J Pediatr Hematol Oncol 1997; 19: 82-5.
30. Ono T, Shiota S, Hirota K, Nemoto K, Tsuchiya T, Miyake Y. Susceptibilities of oral and nasal isolates of Streptococcus mitis and Streptococcus oralis to macrolides and PCR detection of resistance genes. Antimicrob Agents Chemother 2000; 44: 1078-80.
31. Diekema DJ, Beach ML, Pfaller MA, Jones RN, SENTRY Participants Group. Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. Clin Microbiol Infect 2001; 7: 152-7.